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 Mutations differ in normal and cancer cells 
 
[Draft standfirst] 
What determines whether genetic mutations initiate cancer formation? Analyses of healthy 
cells in the human oesophagus reveal that a high level of genetic alterations arise as people 
age yet this doesn’t usually lead to cancer.  
[Standfirst of ~190–225 characters, including spaces.] 
 
Francesca D. Ciccarelli 
 
Errors in DNA replication can alter a cell’s DNA sequence. If such alterations occur early in 
embryonic development, the changes are inherited by all of an organism’s cells. But if these 
alterations arise later in adult life, it is more difficult to track any such change in a small 
number of cells in a specific tissue, so the extent of alteration in normal tissues is poorly 
understood. It is thought that cancer initiates when cells acquire a minimum compendium 
of genetic alterations needed to initiate tumour formation. Understanding when such 
initiating mutations occur in normal cells is crucial to enable the reconstruction of the early 
events that lead to cancer. Writing in Nature, Yokoyama et al.1, and writing in Science, 
Martincorena et al.2 report their respective analyses of the extent of mutations present in 
human epithelial tissue from the healthy oesophagus and their assessments of how this 
illuminates our understanding of the processes that drive cancer development. 
 
Martincorena and colleagues sequenced 74 cancer-associated genes in 844 tissue samples 
taken from the upper oesophagus of nine healthy donors who differed in their gender, age 
and lifestyles. For 21 of these samples, the authors also determined the whole-genome 
sequences. A previous study3 assessing mutations in healthy skin cells reported between 
around two to six mutations per million nucleotides of DNA. By contrast, Martincorena and 
colleagues report that the mutations in oesophageal cells arose at a level approximately 
ten-fold lower than the level reported in skin. This difference was unsurprising because skin 
cells are exposed to more DNA-damaging agents, such as ultraviolet light, than oesophageal 
cells. Instead, the surprise was that healthy oesophagus had more mutations in cancer-
associated genes than were found in healthy skin. Moreover, at least a subset of these 
altered genes was under strong positive selection, meaning that the alterations in the genes 
promoted cell proliferation, giving rise to clonal expansion of such cells. The authors found 
that the donors’ samples had an average of approximately 120 different mutations in 
NOTCH1, a known cancer-associated gene, present per cm2 of normal oesophageal tissue. 
Several of the mutations were of the same type that occurs in the cancer of the upper 
oesophagus called oesophageal squamous cell carcinoma (OSCC).  
 
Yet despite these similarities, there are striking differences between the cell clonal 
expansion of the normal oesophageal epithelium and OSCC. Normal and cancer clones seem 
to be driven by mutations in different genes. NOTCH1 was the most-frequently mutated 
gene in healthy oesophageal cells, whereas a previous study4 reported that NOTCH1 was 
mutated only in around 10% of OSCC. Mutations in the cancer-promoting gene TP53 are 
found in more than 90% of OSCC cases4 but they were present at a much-lower frequency in 
normal oesophageal samples.  
 
In normal cell clones, the prevalent mutational signature — the type of nucleotide changes 
and the DNA context where these occur, was typical of physiological processes such as 
those associated with gene transcription and ageing. Consistent with this, the overall 
number of mutations, as well as the number of mutations in cancer-associated genes and 
the size of the clones were greater in the samples from older people than in the samples 
from younger people. By contrast OSCC is mostly dominated by mutational signatures 
associated with other mutation-causing agents such as, for example, cigarette smoking, 
alcohol intake or an enzyme called APOBEC that can modify DNA5. Another OSCC hallmark is 
chromosomal instability, which causes frequent gene loss or gain4. By contrast, 
Martincorena and colleagues observed low levels of chromosomal instability in healthy 
oesophageal cells.  
 
Yokoyama and colleagues found similar results to those of Martincorena and colleagues. 
Yokoyama et al. analysed 682 samples of healthy and cancerous oesophageal tissue of 139 
individuals, who differed in age and risk of developing OSCC. The authors used a 
combination of approaches to determine DNA sequences ranging from whole-genome 
sequencing and whole-exome (protein-coding regions) sequencing to re-sequencing of 
specific genes. Yokoyama and colleagues found mutations in normal samples from 
cancer[please check as normal seems to contradict the use of ‘cancer’ Mary, a cancer 
patients will have plenty of normal tissue around the cancer and they wanted to see if this 
normal tissue had the same cancer mutations] and healthy individuals. The number of 
mutations in the normal oesophagus increased with an increase in age, clone size and 
exposure to known cancer-risk factors.  
  
Yokoyama et al. also observed most of the same differences between normal and cancer 
cell clones that were noted by Martincorena and colleagues. Using two different 
computational approaches, they identified 24 genes that were frequently mutated in the 
healthy and cancer  samples, but only six of these genes were shared between the two 
groups. As in the study of Martincorena and colleagues, Yokoyama et al. also found that 
TP53 and NOTCH1 were the most commonly mutated genes in cancer and healthy samples, 
respectively. The age-related mutational signature was prevalent in normal oesophageal 
cells, especially those from individuals with a lower risk of developing OSCC. By contrast, 
mutational signatures associated with APOBEC activity or alcohol intake were prevalent in 
cancer samples and detectable in normal samples from higher cancer-risk individuals. They 
detected few chromosomal alterations in normal samples and confirmed the high level of 
chromosomal instability in OSCC.  
 
Both studies offer insights into the evolution of healthy tissues as people age and prompt 
speculations on how this might relate to the development of cancer. The clonal expansion of 
normal oesophageal cells after cancer-promoting genes are mutated seems to be necessary 
but not sufficient to drive cancer, and something else needs to happen to the cells for 
tumours to form. For example, gaining a large-enough number of alterations in cancer-
promoting genes might be needed. In both studies, normal clones carried few mutations 
present in all the cells and many of the cancer-promoting mutations were often found in 
spatially distinct subclones. This suggests that none of the normal cells had acquired enough 
cancer-promoting alterations to start cancer formation. Other missing factors needed to 
drive cancer formation might be of environmental origin.  
 
OSCC occurs frequently in Asia and South America but is rare in the Western world6. The 
reasons underlying this geographical distribution are still mainly unknown, but it is thought 
that lifestyle and environmental factors might have important roles7,8. All the donors 
providing samples for Marincorena and colleagues’ study were from the UK, and it is likely 
that, at least in these cases, the mutated cells lacked the combination of the external factors 
needed to initiate OSCC. By contrast, the samples analysed by Yokoyama and colleagues 
were from Japanese individuals and some of their donors were at high risk of developing 
OSCC. Even in these individuals, however, several normal clones that appeared to have been 
present for a long time had not developed into cancer. For example, a clonal expansion in a 
70-year-old individual with a high risk of developing OSCC probably started with a mutation 
in TP53 at that the authors estimated occurred when the individual was 13 years old. For 
many decades, this cell clone expanded to reach an area of 7 mm2 but it did not develop 
into cancer, confirming that additional unknown factors would be required for that to 
happen. 
 
Another tempting speculation to make concerns the cancer-driving role of NOTCH1 and 
other cancer genes that are more frequently mutated in normal tissue than in cancer. 
Clearly alterations in these genes are not early events in cancer progression. Their relatively 
high mutation frequency in OSCC might be a consequence of the fact that they are often 
mutated in normal tissue rather than an evidence of their function as a cancer driver. If this 
is the case, it challenges the idea that common gene alterations in cancer samples indicate 
genetic changes that are likely to have a cancer-promoting role. Yet this is still the most-
common approach used to identify cancer-associated genes9. 
 
Finally, the role that mutations in genes not involved in cancer might have in the clonal 
expansion of normal tissues remains to be investigated. Given the partially independent 
mechanisms that seem to drive the expansion of normal and cancer clones, perhaps 
mutations in genes involved in other processes, for example genes involved in ageing, might 
be functionally important in normal clones. Martincorena and colleagues only sequenced 
well-known cancer-promoting genes, and therefore this type of analysis was not feasible in 
their study. Yokoyama and colleagues sequenced all protein-coding regions of the genome 
but only used two well-established computational approaches to find cancer-promoting 
mutations in normal samples. Unsurprisingly, they found mostly known cancer genes. 
Interestingly, they found that the gene PAX9, which encodes a transcription factor is 
significantly[is this being used in  the sense of statistical significance? Yes, but ‘at the level 
of statistical significance’ is not used. If you do not like significantly replace with 
commonly] mutated in normal oesophageal tissue, but has not been associated with cancer 
formation so far. This suggests that a less ‘cancer-centric’ analysis of genes might reveal 
other genes that can drive the expansion of clones in normal tissue. We are only starting to 
map the extent of genetic alterations in normal tissues. The next challenges will be to fully 
understand their role in healthy tissues and in disease states. 
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